Health Care [ 8/12 ] | Biotechnology [ 32/76 ]
NASDAQ | Common Stock
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease.
It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.
Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 10.03 K Increased by +N/A% | -1.93 M Decreased by -67.91% | Decreased by -19.27 K% Decreased by N/A% |
| Jun 30, 23 | 1.73 K Increased by +N/A% | -4.02 M Decreased by -377.78% | Decreased by -233.21 K% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -1.03 M Decreased by -256.01% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 950.00 Increased by +N/A% | -2.38 M Decreased by -2.39 K% | Decreased by -250.32 K% - |
| Sep 30, 22 | 0.00 Decreased by N/A% | -1.15 M Decreased by -720.46% | Decreased by N/A% - |
| Jun 30, 22 | 0.00 - | -842.00 K - | Decreased by N/A% - |
| Mar 31, 22 | 0.00 - | -290.06 K - | Decreased by N/A% - |
| Jun 30, 21 | N/A - | -95.45 K - | - - |